Legend Biotech | 6-K: Legend Biotech Announces EU Commission Approval of CARVYKTI for Second-Line Treatment in Patients with Relapsed or Refractory Multiple Myeloma
Legend Biotech | 6-K: Legend Biotech Announces EU Commission Approval of CARVYKTI for Second-Line Treatment in Patients with Relapsed or Refractory Multiple Myeloma
傳奇生物 | 6-K：傳奇生物宣佈CARVYKTI獲歐盟委員會批准用於復發難治性多發性骨髓瘤患者的二線治療
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。